Inpharma 1592 - 16 Jun 2007

■ Ziprasidone has similar effects on schizophrenicpatients in a naturalistic setting as in more restrictedclinical trials, report researchers from Spain. In theirmulticentre, observational trial,* 1022 evaluableoutpatients were prescribed oral ziprasidone for6 months. The mean final dose was 126.6 mg/day.According to the Positive And Negative SyndromeScale (PANSS) scores, 47.3% of patients had achieveda clinical response,** after 6 months of treatment.Significant decreases from baseline were seen in boththe PANSS and the Clinical Global Impressions totalscores; decreases in PANSS total scores weresignificant from week 2. From week 4, significantimprovements were seen in the cognitive symptoms,anxiety-depression, social integration and excitementPANSS subscales.* funded by Pfizer** ≥ 30% reduction in PANSS total score

Arango C, et al. A 6-month prospective, observational, naturalistic,uncontrolled study to evaluate the effectiveness and tolerability of oralziprasidone in patients with schizophrenia. EuropeanNeuropsychopharmacology 17: 456-463, No. 6-7, May-Jun 2007 801077238

1

Inpharma 16 Jun 2007 No. 15921173-8324/10/1592-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved